Compare Gilead Sciences, Inc. (GILD) vs Unilever plc (UL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Unilever plc — how do they compare? Gilead Sciences, Inc. trades at $136.02 (market cap $163.51B), while Unilever plc trades at $62.73 (market cap $129.57B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Unilever plc pays the higher dividend (3.71%). Which is the better fit depends on your goals.
| GILD | UL | |
|---|---|---|
Market Cap | $163.51B | $129.57B |
Sector | Health | Consumer Staples |
52-Week High | $155.80 | $74.59 |
52-Week Low | $108.22 | $55.05 |
Enterprise Value | $178.05B | $155.02B |
Dividend Yield | 2.49% | 3.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Unilever (UL) trades at $62.49, up 2.71% with a bullish technical signal. Recent earnings misses contrast with strong profitability margins and a 53.32% ROE. The company is divesting its food business to McCormick and investing in innovation, while maintaining a $0.54 dividend. Cash flow improved to $1.91B net in 2024 after a volatile period.
Outlook remains mixed: valuation appears fair with a P/E of 20.83, but revenue declines and execution risks on strategic deals pose challenges. Analyst sentiment is cautious with only 24% buy ratings. The stock offers stability through dividends but faces headwinds in sales growth and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Unilever plc
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →
